Clinical efficacy of ZelanteDVT™ catheter rheolytic thrombectomy in the single-session treatment of patients with subacute deep venous thrombosis.

IF 1.6 4区医学 Q3 PERIPHERAL VASCULAR DISEASE Phlebology Pub Date : 2023-09-01 Epub Date: 2023-07-12 DOI:10.1177/02683555231188900

Da Li, Xiaosong Zhang, Yusheng Wang, Hao Tang, He Huang, Xiaomin Huang, Honggang Zhang

{"title":"Clinical efficacy of ZelanteDVT™ catheter rheolytic thrombectomy in the single-session treatment of patients with subacute deep venous thrombosis.","authors":"Da Li, Xiaosong Zhang, Yusheng Wang, Hao Tang, He Huang, Xiaomin Huang, Honggang Zhang","doi":"10.1177/02683555231188900","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the clinical efficacy and safety of novel ZelanteDVT™ catheter rheolytic thrombectomy in the single-session endovascular management of subacute deep venous thrombosis (DVT).Methods: A retrospective study was performed on 31 patients with subacute DVT who underwent ZelanteDVT™ catheter rheolytic thrombectomy. Procedure data, associated complications, and venous patency score were recorded. The deep venous patency and post-thrombotic syndrome (PTS) rate were assessed in all patients during follow-up visits.Results: After procedure, 19.4% (6/31) patients improved to grade III thrombus removal, while the remaining patients improved to grade II. Significant iliac vein compression syndrome was identified in 54.8% (17/31) patients, and 82.4% (14/17) of them received stent implantation. No serious procedure-related complications occurred. The median follow-up time was 13 months. The primary patency rate at 12 months was 83.87%, and the incidence of PTS was 19.35%.Conclusion: This novel rheological thrombectomy catheter seems to have a promising application prospect for single-session treatment of subacute DVT.","PeriodicalId":20139,"journal":{"name":"Phlebology","volume":" ","pages":"523-531"},"PeriodicalIF":1.6000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phlebology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/02683555231188900","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the clinical efficacy and safety of novel ZelanteDVT™ catheter rheolytic thrombectomy in the single-session endovascular management of subacute deep venous thrombosis (DVT).

Methods: A retrospective study was performed on 31 patients with subacute DVT who underwent ZelanteDVT™ catheter rheolytic thrombectomy. Procedure data, associated complications, and venous patency score were recorded. The deep venous patency and post-thrombotic syndrome (PTS) rate were assessed in all patients during follow-up visits.

Results: After procedure, 19.4% (6/31) patients improved to grade III thrombus removal, while the remaining patients improved to grade II. Significant iliac vein compression syndrome was identified in 54.8% (17/31) patients, and 82.4% (14/17) of them received stent implantation. No serious procedure-related complications occurred. The median follow-up time was 13 months. The primary patency rate at 12 months was 83.87%, and the incidence of PTS was 19.35%.

Conclusion: This novel rheological thrombectomy catheter seems to have a promising application prospect for single-session treatment of subacute DVT.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

ZelandeDVT的临床疗效™ 导管溶栓治疗亚急性深静脉血栓形成患者的单次治疗。

目的：评价新型ZelandeDVT的临床疗效和安全性™ 导管溶栓术在亚急性深静脉血栓形成（DVT）单次血管内治疗中的应用方法：对31例接受ZelandeDVT的亚急性DVT患者进行回顾性研究™ 导管溶栓血栓切除术。记录手术数据、相关并发症和静脉通畅性评分。在随访期间评估所有患者的深静脉通畅率和血栓形成后综合征（PTS）发生率。结果：术后，19.4%（6/31）的患者病情好转至III级血栓清除，其余患者病情好转为II级。54.8%（17/31）的患者发现了严重的髂静脉压迫综合征，其中82.4%（14/17）的患者接受了支架植入。没有发生严重的手术并发症。中位随访时间为13个月。12个月时初次通畅率为83.87%，PTS发生率为19.35%。结论：这种新型流变性血栓切除导管在亚急性DVT的单次治疗中具有良好的应用前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Phlebology 医学-外周血管病

CiteScore

3.30

自引率

11.80%

发文量

审稿时长

6-12 weeks

期刊介绍： The leading scientific journal devoted entirely to venous disease, Phlebology is the official journal of several international societies devoted to the subject. It publishes the results of high quality studies and reviews on any factor that may influence the outcome of patients with venous disease. This journal provides authoritative information about all aspects of diseases of the veins including up to the minute reviews, original articles, and short reports on the latest treatment procedures and patient outcomes to help medical practitioners, allied health professionals and scientists stay up-to-date on developments. Print ISSN: 0268-3555